Mr. Alex Blanchard reports

LEXARIA BIOSCIENCE CORP. RECEIVES NEW GRANTED PATENTS

Lexaria Bioscience Corp. has received notifications that it has received two new U.S. patents granted and additionally expects three new Australian patents granted on or before Aug. 17.

Once granted, Lexaria will have four granted patents in the United States and four granted patents in Australia. All eight of these patents are within Lexaria's first patent family "Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof" and significantly strengthen Lexaria's intellectual property claims in the U.S. and Australia.

Of note, the new Australian patents expand Lexaria's intellectual property protection to include the delivery of all cannabinoids, psychoactive and non-psychoactive; nicotine; NSAIDs, including but not limited to ibuprofen; and fat-soluble vitamins such as vitamins A, D, E and K. This represents the first time that Lexaria has received patent protection for delivery of molecules other than cannabinoids outside of the U.S.

Lexaria's patent portfolio continues to grow, now with more than 40 patent applications or awards in over 40 countries around the world. Additional new patent application filings for new patent families as a result of research and development programs are currently being prepared and Lexaria continues to expect further patent awards this year. As its patent portfolio expands, Lexaria will be better able to commercialize its technologies and defend its intellectual property.

Separately, Lexaria announces it has received $24,500 (U.S.) from the exercise of warrants previously granted. The company has received for exercise a total of 175,000 warrants with an exercise price of 14 U.S. cents, previously granted. The warrant exercises are by a third party who is neither an officer nor a director of the company.

No commissions or placement fees have been paid related to the funds received from these warrants exercised. Proceeds will be used for general corporate purposes.

About Lexaria Bioscience Corp.

Lexaria Bioscience has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the U.S. and in Australia for utilization of its DehydraTECH delivery technology. Lexaria's technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules, including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

We seek Safe Harbor.